Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 239S · 10 late239 trades$59.22M
Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 7 | Sibold William JohnDirector, President and CEO |  MDGLMADRIGAL PHARMACEUTICALS, INC.Open-market sale · 10b5-1 plan | SELL | $277K 522 sh |
| Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $558K 1,040 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $273K 512 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $345K 644 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 7 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $273K 505 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 6 | Feeley KevinCHIEF FINANCIAL OFFICER |  WGSGeneDx Holdings Corp.Option exercise | M | — 2,462 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER | WGSGeneDx Holdings Corp. Option exercise | M | — 6,547 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Mercier JohannaChief Comm & Corp Aff Officer |  GILDGILEAD SCIENCES, INC.Option exercise | M | — 2,797 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER |  LTHLife Time Group Holdings, Inc.Option exercise | M | — 59.4K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | O'Day Daniel PatrickDirector, Chairman & CEO | GILDGILEAD SCIENCES, INC. Option exercise | M | — 8,780 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER | LTHLife Time Group Holdings, Inc. Option exercise | M | — 34.8K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Rogers George Ted IIIDirector |  GREEVulcan Infrastructure & Power Inc.Derivative conversion | C | — 16.0K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Gracey CraigChief Accounting Officer |  OMDAOmada Health, Inc.Open-market sale · 10b5-1 plan | SELL | $14K 644 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 5 | Singh Ritadhwaja JebensEVP & CHIEF DIGITAL OFFICER | LTHLife Time Group Holdings, Inc. Option exercise | M | — 60.7K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Rogers George Ted IIIDirector | GREEVulcan Infrastructure & Power Inc. Derivative conversion | C | — 16.0K sh | Sep 11, 2026 traded Sep 11, 2026 |
| 5 | Malady KyleEVP and Group CEO-VZ Business |  VZVERIZON COMMUNICATIONS INCGrant or award | A | $1,738 122 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $212K 396 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner |  HNGEHinge Health, Inc.Derivative conversion · 10b5-1 plan | C | — 150.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 4 | Perez Daniel AntonioDirector, CEO & Co-Founder, 10% Owner | HNGEHinge Health, Inc. Derivative conversion · 10b5-1 plan | C | — 150.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $184K 347 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $371K 687 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $652K 1,202 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Tsao DavidDirector, Chief Technology Officer | BLLNBillionToOne, Inc. Option exercise · 10b5-1 plan | M | $28K 10.0K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $196K 362 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $196K 368 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $87K 160 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Tsao DavidDirector, Chief Technology Officer | BLLNBillionToOne, Inc. Option exercise · 10b5-1 plan | M | $28K 10.0K sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $69K 131 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $415K 761 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $116K 215 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 4 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $837K 1,539 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 3 | Brosius MarkEVP & Chief Mfg and Supply Cha | ISRGINTUITIVE SURGICAL INC Open-market sale · 10b5-1 plan | SELL | $9,145 25 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 3 | Tak Paul PeterDirector, Chief Executive Officer |  CADLCandel Therapeutics, Inc.Option exercise · 10b5-1 plan | M | — 125.0K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 3 | Sullivan Christopher RyanChief Financial Officer |  AVTXAvalo Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $82K 10.2K sh | Sep 11, 2026 traded Sep 10, 2026 |
| 3 | Brosius MarkEVP & Chief Mfg and Supply Cha | ISRGINTUITIVE SURGICAL INC Open-market sale · 10b5-1 plan | SELL | $7,996 23 sh | Sep 11, 2026 traded Sep 10, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $199K 368 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Arora TarunChief Accounting Officer |  RNGRingCentral, Inc.Open-market sale · 10b5-1 plan | SELL | $104K 1,493 sh | Sep 11, 2026 traded Sep 9, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $117K 218 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $86K 160 sh | Sep 11, 2026 traded Sep 11, 2026 |
| 1 | Sibold William JohnDirector, President and CEO | MDGLMADRIGAL PHARMACEUTICALS, INC. Open-market sale · 10b5-1 plan | SELL | $66K 120 sh | Sep 11, 2026 traded Sep 11, 2026 |
